UAE Diabetes Drugs Market By Drug Class (Insulin, DPP-4 Inhibitors, GLP-1 Receptor Agonists, SGLT2 Inhibitors, Others); By Diabetes Types (Type 1, Type 2, Diabetes Type 3, Diabetes Type 4, Diabetes Type 5); By Route of Administration (Oral, Subcutaneous, Intravenous, Route of Administration 4, Route of Administration 5); By Technology (Technology 1, Technology 2, Technology 3); By Distribution Channel (Online Pharmacies, Hospital Pharmacies, Retail Pharmacies, Distribution Channel 4, Distribution Channel 5) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032
Price: $2699
Published: | Report ID: 83906 | Report Format : Excel, PDF
UAE Diabetes Drugs Market size was valued at USD 176.85 million in 2023 and is anticipated to reach USD 198.02 million by 2032, at a CAGR of 0.85% during the forecast period (2023-2032).
The UAE Diabetes Drugs market is primarily driven by the rising prevalence of diabetes, fueled by lifestyle changes, unhealthy diets, and increasing urbanization. As the population grows older and more individuals are diagnosed with type 2 diabetes, the demand for effective treatments rises. Additionally, the market benefits from advancements in drug formulations, including oral medications and insulin alternatives, improving disease management and patient outcomes. The increasing awareness of diabetes and its complications, alongside government initiatives to promote health and wellness, further propels market growth. Additionally, the growing focus on personalized medicine and the development of innovative therapies are driving new drug introductions, contributing to a diverse treatment landscape. As a result, the market is expected to experience gradual expansion, reflecting both the increasing burden of diabetes and the continuous evolution of the pharmaceutical landscape in the UAE.
The UAE Diabetes Drugs market is influenced by the regional healthcare infrastructure and the rising prevalence of diabetes across the emirates. Dubai and Abu Dhabi, with their advanced healthcare systems and growing awareness campaigns, are central to the market’s expansion. These cities attract a diverse population, including expatriates, which increases the demand for diabetes treatments. Sharjah and other northern emirates are witnessing growing demand as well, with healthcare services gradually improving to meet the needs of diabetic patients. Key players in the UAE Diabetes Drugs market include global pharmaceutical giants such as Novo Nordisk, Eli Lilly and Company, Merck & Co., Inc., and Sanofi, which offer a broad range of diabetes medications. These companies are capitalizing on the growing need for innovative therapies, from insulin injections to oral medications and biologics, while also focusing on patient-centric solutions to address the increasing diabetes burden in the region.
Access crucial information at unmatched prices!
Request your sample report today & start making informed decisions powered by Credence Research!
The UAE Diabetes Drugs market was valued at USD 176.85 million in 2023 and is expected to reach USD 198.02 million by 2032, with a CAGR of 0.85%.
The increasing prevalence of diabetes, particularly type 2, is a key driver of market growth.
Advancements in drug formulations, including non-insulin therapies, are driving market expansion.
Digital health solutions, including mobile apps and continuous glucose monitoring, are becoming integrated with diabetes treatments, enhancing patient outcomes.
The market is highly competitive, with key players like Novo Nordisk, Eli Lilly, and Merck & Co. dominating the landscape.
High treatment costs and limited public awareness remain significant market restraints.
Dubai and Abu Dhabi lead the market, with growing demand also seen in Sharjah and northern emirates, supported by improving healthcare infrastructure.
Report Scope
This report segments the UAE Diabetes Drugs Market as follows:
Market Drivers
Rising Prevalence of Diabetes
One of the primary drivers of the UAE Diabetes Drugs market is the increasing prevalence of diabetes within the population. The UAE has seen a rapid rise in the number of individuals diagnosed with type 2 diabetes due to lifestyle changes such as poor dietary habits, sedentary behavior, and increasing urbanization. The country is witnessing a higher incidence of obesity, a major risk factor for developing diabetes, particularly among the younger population. According to the International Diabetes Federation, the UAE has one of the highest rates of diabetes in the world, prompting a growing demand for diabetes medications. This surge in diabetes cases has created a significant market opportunity for pharmaceutical companies to offer effective treatments to manage the condition.
Increasing Government Health Initiatives
Government initiatives aimed at promoting health and combating chronic diseases such as diabetes play a crucial role in driving the demand for diabetes drugs in the UAE. For instance, MoHAP launched the National Prediabetes and Diabetes Screening campaign in 2023, offering free screenings and follow-up consultations to promote early detection and management. The UAE government has implemented various national programs focusing on diabetes prevention, early detection, and management. These initiatives are coupled with awareness campaigns, screening programs, and educational efforts to inform the public about the importance of diabetes care. Moreover, the government’s active engagement in improving healthcare infrastructure, along with policies supporting the availability of affordable and accessible treatment options, is contributing to the growth of the diabetes drug market. As more individuals are diagnosed and treated, the demand for diabetes medications continues to rise.
Advancements in Drug Formulations
The continuous advancements in diabetes drug formulations are significantly driving the market in the UAE. There has been a rise in the availability of innovative medications, including oral hypoglycemics and insulin alternatives, which cater to the diverse needs of diabetic patients. These newer drug formulations offer better efficacy, improved safety profiles, and ease of administration compared to older treatments. For instance, the introduction of GLP-1 receptor agonists, SGLT-2 inhibitors, and novel insulin therapies have provided more options for personalized treatment, enhancing patient outcomes. As the therapeutic landscape evolves, the availability of better treatment options is likely to continue driving market growth in the UAE.
Growing Focus on Personalized Medicine
The shift toward personalized medicine is another key driver for the UAE Diabetes Drugs market. Personalized medicine tailors treatment plans to individual patients based on genetic, environmental, and lifestyle factors, ensuring more effective and targeted care. For instance, research initiatives at Khalifa University are exploring pharmacogenomics to optimize diabetes treatments based on genetic profiles, paving the way for precision medicine in the UAE. With advancements in genomics and biotechnology, pharmaceutical companies are increasingly developing drugs that can address specific patient profiles, making treatment more efficient. In the UAE, this trend is gaining momentum, particularly as patients seek treatments that are better suited to their unique health conditions. As personalized treatment options expand, the demand for specialized diabetes drugs is expected to grow, driving innovation and growth within the market.
Market Trends
Shift Towards Non-Insulin Therapies
One prominent trend in the UAE Diabetes Drugs market is the growing preference for non-insulin therapies, especially for type 2 diabetes management. Oral medications such as SGLT-2 inhibitors, GLP-1 receptor agonists, and DPP-4 inhibitors are becoming increasingly popular due to their ease of use, fewer side effects, and ability to provide better glycemic control without the need for injections. For instance, the Emirates Diabetes Society has endorsed the use of GLP-1 receptor agonists for their dual benefits in glycemic control and weight management, particularly for patients with obesity-related diabetes. These non-insulin therapies are designed to manage blood glucose levels effectively, improve patient compliance, and offer additional benefits, such as weight loss and cardiovascular protection. As the demand for less invasive treatment options grows, non-insulin drugs are becoming a key component of diabetes management in the UAE.
Integration of Digital Health Solutions
Another growing trend in the UAE Diabetes Drugs market is the integration of digital health solutions in diabetes management. Digital health tools such as mobile apps, wearable devices, and continuous glucose monitoring (CGM) systems are increasingly being used to help patients manage their condition more effectively. For instance, the Dubai Health Authority (DHA) has implemented telemedicine platforms that integrate CGM data with patient records, enabling real-time monitoring and personalized treatment adjustments. These tools allow for real-time monitoring of blood glucose levels, medication adherence, and lifestyle factors, providing valuable insights for both patients and healthcare providers. The integration of these technologies with diabetes drugs offers a comprehensive approach to managing the disease, improving patient outcomes, and enhancing overall treatment efficacy. This trend is expected to continue as digital health solutions become more widespread and accessible in the UAE.
Focus on Patient-Centric Treatment Approaches
There is an increasing focus on patient-centric treatment approaches in the UAE Diabetes Drugs market. The shift towards personalized medicine, where treatment plans are tailored to individual patient needs, is gaining traction. This trend involves considering factors such as the patient’s genetic makeup, lifestyle, comorbidities, and preferences to optimize drug therapies. By adopting a more patient-centered approach, healthcare providers can ensure better treatment outcomes, minimize side effects, and improve patient satisfaction. This trend reflects the broader global movement toward precision medicine and is becoming a key factor driving the development and adoption of diabetes drugs in the UAE.
Growing Popularity of Biologic Drugs
Biologic drugs are becoming increasingly popular in the UAE Diabetes Drugs market, especially as treatments for type 1 diabetes and severe cases of type 2 diabetes. These biologic agents, such as biosimilar insulins and GLP-1 receptor agonists, offer more targeted and effective solutions for controlling blood sugar levels. Biologics are often preferred by patients who have not responded well to traditional oral therapies, as they can offer more effective glycemic control and additional health benefits. The growing acceptance and use of biologic drugs in the UAE reflects a broader trend toward innovative treatments that offer enhanced precision and improved quality of life for diabetic patients. As research and development in biologic therapies continue, their market presence is expected to grow significantly.
Market Challenges Analysis
High Cost of Diabetes Drugs
A significant challenge in the UAE Diabetes Drugs market is the high cost of diabetes medications, particularly for advanced therapies such as biologic drugs and newer insulin alternatives. These treatments often come with substantial price tags, which can be a barrier to access for a large portion of the population. For instance, a study published in the International Journal of Diabetes in Developing Countries estimated that the direct annual cost of diabetes treatment in the UAE averages USD 2,968 per person, with biologic drugs and insulin alternatives accounting for a significant portion. While the UAE has a relatively advanced healthcare system, the affordability of these medications remains a concern, especially for individuals without comprehensive health insurance coverage. The high cost of treatment may limit patient adherence to prescribed regimens and create financial strain for both healthcare providers and patients. Addressing this issue will be crucial for ensuring that effective diabetes care remains accessible to all segments of the population.
Limited Public Awareness and Education
Another challenge faced by the UAE Diabetes Drugs market is the limited public awareness and education surrounding diabetes management. Despite the growing prevalence of the disease, many individuals still lack adequate knowledge about proper diabetes care, medication adherence, and the long-term implications of poorly managed diabetes. This lack of awareness can result in delayed diagnoses, improper medication usage, and a higher burden on the healthcare system. Although government initiatives are addressing this issue through health campaigns, the challenge remains in ensuring that the population fully understands the importance of diabetes treatment and the range of available medications. Increased education efforts are needed to bridge this gap and promote better disease management.
Market Opportunities
The UAE Diabetes Drugs market presents several key opportunities driven by the growing prevalence of diabetes and the evolving treatment landscape. As the number of diabetes cases continues to rise, there is an increasing demand for both established and innovative drug therapies. This provides pharmaceutical companies with an opportunity to expand their portfolios by introducing advanced drug formulations that offer better efficacy and improved patient outcomes. The market is particularly poised for growth in non-insulin therapies, such as GLP-1 receptor agonists, SGLT-2 inhibitors, and DPP-4 inhibitors, which are gaining popularity due to their ease of use, lower side-effect profiles, and potential benefits for comorbid conditions like cardiovascular diseases. As healthcare providers look to offer more personalized treatment options, companies can capitalize on this trend by developing tailored solutions that cater to individual patient needs.
Furthermore, the increasing integration of digital health solutions presents a significant market opportunity. The adoption of mobile apps, wearable devices, and continuous glucose monitoring (CGM) systems is helping patients better manage their diabetes by providing real-time data and improving medication adherence. The growing trend of combining drug therapies with digital health tools creates a comprehensive approach to diabetes care, which is expected to enhance patient outcomes and drive market growth. Additionally, the UAE government’s efforts to improve public health awareness and accessibility to healthcare services create a favorable environment for the growth of the diabetes drug market. With a focus on prevention, early detection, and management, there are numerous opportunities for both local and international companies to introduce innovative treatments and support the healthcare infrastructure.
Market Segmentation Analysis:
By Drug Class:
The UAE Diabetes Drugs market is characterized by a variety of drug classes designed to meet the different needs of diabetic patients. Insulin remains the cornerstone of treatment for type 1 diabetes, and is also used for managing advanced cases of type 2 diabetes. However, the demand for non-insulin therapies has risen significantly in recent years, driven by the adoption of more patient-friendly treatments. DPP-4 inhibitors, such as sitagliptin, are increasingly used for type 2 diabetes due to their ability to enhance insulin secretion and reduce blood sugar levels with fewer side effects. GLP-1 receptor agonists, such as liraglutide, are gaining popularity for their dual benefits of improving glycemic control and promoting weight loss. SGLT2 inhibitors, like empagliflozin, offer additional advantages such as cardiovascular protection and weight reduction, making them a preferred choice for managing type 2 diabetes. Other drug classes, including sulfonylureas and thiazolidinediones, continue to play a role in diabetes management, though their market share is gradually decreasing.
By Diabetes Types:
The UAE Diabetes Drugs market is further segmented based on the type of diabetes being treated, with type 2 diabetes accounting for the largest share. As the most common form of diabetes in the UAE, type 2 diabetes drives the demand for a range of oral and injectable medications, including GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors. Type 1 diabetes, while less prevalent, still represents a significant portion of the market, primarily requiring insulin therapy for lifelong management. Emerging conditions, such as diabetes type 3, which is associated with Alzheimer’s disease, and diabetes type 4, linked to obesity, are creating a new demand for specialized therapies targeting both blood glucose control and related comorbidities. Diabetes type 5 and other newly classified forms of diabetes are also beginning to influence the market, though these are still in early stages of research and treatment development. As awareness and diagnoses of various diabetes types increase, there is growing potential for specialized treatments tailored to these distinct forms of diabetes.
Segments:
Based on Drug Class:
Insulin
DPP-4 Inhibitors
GLP-1 Receptor Agonists
SGLT2 Inhibitors
Others
Based on Diabetes Types:
Type 1
Type 2
Diabetes Type 3
Diabetes Type 4
Diabetes Type 5
Based on Route of Administration:
Oral
Subcutaneous
Intravenous
Route of Administration 4
Route of Administration 5
Based on Technology:
Technology 1
Technology 2
Technology 3
Based on Distribution Channel:
Online Pharmacies
Hospital Pharmacies
Retail Pharmacies
Distribution Channel 4
Distribution Channel 5
Based on the Geography:
Abu Dhabi
Dubai
Sharjah
Ajman
Fujairah
Ras Al Khaimah
Umm Al Quwain
Regional Analysis
Dubai
Dubai leads the market, holding the largest share, accounting for approximately 35% of the total market. As the commercial and healthcare hub of the UAE, Dubai has a high concentration of both diabetes cases and healthcare facilities. The city’s advanced healthcare infrastructure, coupled with its diverse population, drives the demand for a wide range of diabetes medications. Additionally, Dubai’s significant expatriate population and growing healthcare tourism contribute to the market’s expansion. The continuous efforts to enhance healthcare services in Dubai further fuel the growth of the diabetes drugs market.
Abu Dhabi
Abu Dhabi follows as the second-largest contributor to the UAE diabetes drug market, commanding around 30% of the market share. As the capital of the UAE, Abu Dhabi benefits from strong government initiatives to combat diabetes, making it a crucial region for diabetes care. The emirate’s healthcare system is well-developed, with an increasing focus on public health awareness campaigns targeting diabetes prevention and management. The high prevalence of diabetes in Abu Dhabi, coupled with its affluent population, results in a substantial demand for both traditional and advanced diabetes medications. Additionally, Abu Dhabi’s healthcare facilities and research institutions are continuously contributing to the availability of new treatment options.
Sharjah
Sharjah, with a market share of approximately 15%, represents a growing segment of the UAE Diabetes Drugs market. As the third-largest emirate, Sharjah has witnessed an increase in diabetes cases, driven by factors such as urbanization, lifestyle changes, and rising obesity rates. The government’s investment in healthcare infrastructure, alongside increasing awareness of diabetes and its management, is driving the demand for diabetes medications in Sharjah. The emirate is also home to a significant number of industrial workers, many of whom face an elevated risk of developing diabetes, contributing to the growing need for effective treatments.
Ajman, Fujairah, Ras Al Khaimah, and Umm Al Quwain
The remaining regions, including Ajman, Fujairah, Ras Al Khaimah, and Umm Al Quwain, collectively account for around 20% of the market share. Among these, Ajman and Ras Al Khaimah are seeing moderate growth, with an increasing number of diabetes cases in line with the national trend. Fujairah and Umm Al Quwain have smaller shares of the market, but their growing healthcare initiatives and increasing healthcare access are expected to boost the demand for diabetes drugs in the coming years. As these regions continue to develop their healthcare sectors, they present untapped opportunities for pharmaceutical companies to expand their reach and introduce innovative diabetes treatments.
Key Player Analysis
Novo Nordisk A/S
Sanofi
Merck & Co., Inc
Eli Lilly and Company
AstraZeneca
Takeda Pharmaceutical Company Limited
Boehringer Ingelheim International GmbH
Novartis AG
Johnson & Johnson Services, Inc.
Bayer AG
NeoBiocon
NewBridge Pharmaceuticals FZ LLC
Competitive Analysis
The UAE Diabetes Drugs market is highly competitive, with several leading global pharmaceutical companies driving the industry. Key players in the market include Novo Nordisk, Eli Lilly and Company, Merck & Co., Inc., Sanofi, AstraZeneca, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Novartis AG, Johnson & Johnson Services, Inc., Bayer AG, NeoBiocon, and NewBridge Pharmaceuticals FZ LLC. These companies offer a broad range of diabetes medications, from traditional insulin therapies to newer non-insulin treatments such as GLP-1 receptor agonists, DPP-4 inhibitors, and SGLT2 inhibitors. These therapies not only aim at controlling blood sugar but also address comorbidities like cardiovascular diseases, which are increasingly prevalent in diabetic patients. The market is also characterized by aggressive strategies including product innovation, strategic collaborations, and acquisitions to strengthen market positioning. Companies are investing heavily in research and development to bring advanced treatment options that cater to diverse patient needs. Additionally, the growing integration of digital health solutions, such as continuous glucose monitoring systems and diabetes management apps, is shaping the competitive landscape. To stay ahead, market players must also navigate challenges such as high treatment costs and regulatory hurdles while working to enhance patient access to effective diabetes care across the UAE.
Recent Developments
In March 2025, Novo Nordisk signed a deal worth up to $2 billion for the rights to UBT251, a new obesity and diabetes drug developed by United BioTechnology. The drug combines GLP-1, GIP, and glucagon to manage blood sugar and reduce hunger.
In February 2025, Sanofi received FDA approval for MERILOG, the first rapid-acting insulin aspart biosimilar, to improve glycemic control in adults and pediatric patients with diabetes.
In December 2024, JD Health began offering Merck’s GLUCOPHAGE XR (Reduce Mass) online in China, enhancing access to metformin hydrochloride extended-release tablets for type 2 diabetes patients.
In December 2024, Torrent Pharma acquired three diabetes brands from Boehringer Ingelheim, including those with Empagliflozin, to strengthen its anti-diabetes portfolio
In November 2024, AstraZeneca presented promising early data for its obesity pipeline, including AZD5004, an oral GLP-1 receptor blocker, at ObesityWeek 2024.
Market Concentration & Characteristics
The UAE Diabetes Drugs market exhibits moderate concentration, with a mix of global pharmaceutical giants and regional players dominating the landscape. A few key multinational companies control a significant share of the market, particularly in insulin therapies and newer drug classes such as GLP-1 receptor agonists and SGLT2 inhibitors. These companies maintain a competitive edge through continuous innovation, extensive product portfolios, and strong distribution networks. However, the presence of local players and new entrants focused on developing region-specific solutions also contributes to market fragmentation. The market is characterized by a growing emphasis on patient-centric treatments, with a shift towards non-insulin therapies and integrated digital health solutions. The increasing demand for personalized medicine, which tailors treatment plans to individual patient needs, is also shaping the competitive dynamics. Despite the dominance of established players, the market remains dynamic, offering opportunities for new and emerging companies to capitalize on the evolving demand for diabetes management solutions in the UAE.
Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!
The research report offers an in-depth analysis based on Drug Class,Diabetes Types, Route of Administration, Technology, Distribution Channeland Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.
Future Outlook
The UAE Diabetes Drugs market is expected to experience steady growth due to the rising prevalence of diabetes in the region.
Increasing demand for non-insulin therapies, such as GLP-1 receptor agonists and SGLT2 inhibitors, will drive market expansion.
The adoption of personalized medicine tailored to individual patient profiles will shape the future of diabetes treatments.
Digital health solutions, including continuous glucose monitoring and diabetes management apps, will become more integrated with drug therapies.
Innovation in biologic drugs will lead to more targeted treatments, particularly for type 1 and advanced type 2 diabetes.
The UAE government’s focus on healthcare infrastructure and public awareness will further boost market growth.
Rising healthcare accessibility and affordability will make diabetes drugs more available to a wider population.
There will be increased emphasis on the management of comorbidities, such as cardiovascular diseases, in diabetes treatments.
Growing competition will foster the introduction of more affordable and effective diabetes medications.
The market will see greater collaboration between global pharmaceutical companies and regional healthcare providers to address local needs.
CHAPTER NO. 1 : INTRODUCTION 19
1.1.1. Report Description 19 Purpose of the Report 19 USP & Key Offerings 19
1.1.2. Key Benefits for Stakeholders 19
1.1.3. Target Audience 20
1.1.4. Report Scope 20 CHAPTER NO. 2 : EXECUTIVE SUMMARY 21
2.1. DIABETES DRUGS Market Snapshot 21
2.1.1. UAE DIABETES DRUGS Market, 2018 – 2032 (USD Million) 22 CHAPTER NO. 3 : GEOPOLITICAL CRISIS IMPACT ANALYSIS 23
3.1. Russia-Ukraine and Israel-Palestine War Impacts 23 CHAPTER NO. 4 : DIABETES DRUGS MARKET – INDUSTRY ANALYSIS 24
4.1. Introduction 24
4.2. Market Drivers 25
4.2.1. Driving Factor 1 Analysis 25
4.2.2. Driving Factor 2 Analysis 26
4.3. Market Restraints 27
4.3.1. Restraining Factor Analysis 27
4.4. Market Opportunities 28
4.4.1. Market Opportunity Analysis 28
4.5. Porter’s Five Forces Analysis 29
4.6. Value Chain Analysis 30
4.7. Buying Criteria 31 CHAPTER NO. 5 : IMPORT EXPORT ANALYSIS 32
5.1. Import Analysis by UAE 32
5.1.1. UAE DIABETES DRUGS Market Import Volume/Revenue, By UAE, 2018 – 2023 32
5.2. Export Analysis by UAE 33
5.2.1. UAE DIABETES DRUGS Market Export Volume/Revenue, By UAE, 2018 – 2023 33 CHAPTER NO. 6 : DEMAND SUPPLY ANALYSIS 34
6.1. Demand Analysis by UAE 34
6.1.1. UAE DIABETES DRUGS Market Demand Volume/Revenue, By UAE, 2018 – 2023 34
6.2. Supply Analysis by UAE 35
6.2.1. UAE DIABETES DRUGS Market Supply Volume/Revenue, By UAE, 2018 – 2023 35 CHAPTER NO. 7 : PRODUCTION ANALYSIS 36
7.1. Production Analysis by UAE 36
7.1.1. UAE DIABETES DRUGS Market Production Volume/Revenue, By UAE, 2018 – 2023 36 CHAPTER NO. 8 : PRICE ANALYSIS 37
8.1. Price Analysis by Drug Class 37
8.1.1. UAE DIABETES DRUGS Market Price, By Drug Class, 2018 – 2023 37
8.1.2. UAE Drug Class Market Price, By Drug Class, 2018 – 2023 37 CHAPTER NO. 9 : RAW MATERIALS ANALYSIS 38
9.1. Key Raw Materials and Suppliers 38
9.2. Key Raw Materials Price Trend 38 CHAPTER NO. 10 : MANUFACTURING COST ANALYSIS 39
10.1. Manufacturing Cost Analysis 39
10.2. Manufacturing Process 39 CHAPTER NO. 11 : ANALYSIS COMPETITIVE LANDSCAPE 40
11.1. Company Market Share Analysis – 2023 40
11.1.1. UAE DIABETES DRUGS Market: Company Market Share, by Volume, 2023 40
11.1.2. UAE DIABETES DRUGS Market: Company Market Share, by Revenue, 2023 41
11.1.3. UAE DIABETES DRUGS Market: Top 6 Company Market Share, by Revenue, 2023 41
11.1.4. UAE DIABETES DRUGS Market: Top 3 Company Market Share, by Revenue, 2023 42
11.2. UAE DIABETES DRUGS Market Company Volume Market Share, 2023 43
11.3. UAE DIABETES DRUGS Market Company Revenue Market Share, 2023 44
11.4. Company Assessment Metrics, 2023 45
11.4.1. Stars 45
11.4.2. Emerging Leaders 45
11.4.3. Pervasive Players 45
11.4.4. Participants 45
11.5. Start-ups /SMEs Assessment Metrics, 2023 45
11.5.1. Progressive Companies 45
11.5.2. Responsive Companies 45
11.5.3. Dynamic Companies 45
11.5.4. Starting Blocks 45
11.6. Strategic Developments 46
11.6.1. Acquisitions & Mergers 46 New Product Launch 46 UAE Expansion 46
11.7. Key Players Product Matrix 47 CHAPTER NO. 12 : PESTEL & ADJACENT MARKET ANALYSIS 48
12.1. PESTEL 48
12.1.1. Political Factors 48
12.1.2. Economic Factors 48
12.1.3. Social Factors 48
12.1.4. Technological Factors 48
12.1.5. Environmental Factors 48
12.1.6. Legal Factors 48
12.2. Adjacent Market Analysis 48 CHAPTER NO. 13 : DIABETES DRUGS MARKET – BY DRUG CLASS SEGMENT ANALYSIS 49
13.1. DIABETES DRUGS Market Overview, by Drug Class Segment 49
13.1.1. DIABETES DRUGS Market Revenue Share, By Drug Class, 2023 & 2032 50
13.1.2. DIABETES DRUGS Market Attractiveness Analysis, By Drug Class 51
13.1.3. Incremental Revenue Growth Opportunity, by Drug Class, 2024 – 2032 51
13.1.4. DIABETES DRUGS Market Revenue, By Drug Class, 2018, 2023, 2027 & 2032 52
13.2. Insulin 53
13.3. Dpp-4 Inhibitors 54
13.4. GLP-1 Receptor Agonists 55
13.5. SGLT2 Inhibitors 56
13.6. Others 57 CHAPTER NO. 14 : DIABETES DRUGS MARKET – BY DIABETES TYPES SEGMENT ANALYSIS 58
14.1. DIABETES DRUGS Market Overview, by Diabetes Types Segment 58
14.1.1. DIABETES DRUGS Market Revenue Share, By Diabetes Types, 2023 & 2032 59
14.1.2. DIABETES DRUGS Market Attractiveness Analysis, By Diabetes Types 60
14.1.3. Incremental Revenue Growth Opportunity, by Diabetes Types, 2024 – 2032 60
14.1.4. DIABETES DRUGS Market Revenue, By Diabetes Types, 2018, 2023, 2027 & 2032 61
14.2. Type 1 62
14.3. Type 2 63
14.4. Diabetes Types 3 64
14.5. Diabetes Types 4 65
14.6. Diabetes Types 5 66 CHAPTER NO. 15 : DIABETES DRUGS MARKET – BY ROUTE OF ADMINISTRATION SEGMENT ANALYSIS 67
15.1. DIABETES DRUGS Market Overview, by Route Of Administration Segment 67
15.1.1. DIABETES DRUGS Market Revenue Share, By Route Of Administration , 2023 & 2032 68
15.1.2. DIABETES DRUGS Market Attractiveness Analysis, By Route Of Administration 69
15.1.3. Incremental Revenue Growth Opportunity, by Route Of Administration , 2024 – 2032 69
15.1.4. DIABETES DRUGS Market Revenue, By Route Of Administration , 2018, 2023, 2027 & 2032 70
15.2. Oral 71
15.3. Subcutaneous 72
15.4. Intravenous 73
15.5. Route Of Administration 4 74
15.6. Route Of Administration 5 75 CHAPTER NO. 16 : DIABETES DRUGS MARKET – BY TECHNOLOGY SEGMENT ANALYSIS 76
16.1. DIABETES DRUGS Market Overview, by Technology Segment 76
16.1.1. DIABETES DRUGS Market Revenue Share, By Technology, 2023 & 2032 77
16.1.2. DIABETES DRUGS Market Attractiveness Analysis, By Technology 78
16.1.3. Incremental Revenue Growth Opportunity, by Technology, 2024 – 2032 78
16.1.4. DIABETES DRUGS Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79
16.2. Technology 1 80
16.3. Technology 2 81
16.4. Technology 3 82 CHAPTER NO. 17 : – BY DISTRIBUTION CHANNEL SEGMENT ANALYSIS 83
17.1. DIABETES DRUGS Market Overview, by Distribution Channel Segment 83
17.1.1. DIABETES DRUGS Market Revenue Share, By Distribution Channel, 2023 & 2032 84
17.1.2. DIABETES DRUGS Market Attractiveness Analysis, By Distribution Channel 85
17.1.3. Incremental Revenue Growth Opportunity, by Distribution Channel, 2024 – 2032 85
17.1.4. DIABETES DRUGS Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86
17.2. Online Pharmacies 87
17.3. Hospital Pharmacies 88
17.4. Retail Pharmacies 89
17.5. Distribution Channel 4 90
17.6. Distribution Channel 5 91 CHAPTER NO. 18 : DIABETES DRUGS MARKET – UAE ANALYSIS 92
18.1. Drug Class 92
18.1.1. UAE DIABETES DRUGS Market Revenue, By Drug Class, 2018 – 2023 (USD Million) 92
18.2. UAE DIABETES DRUGS Market Revenue, By Drug Class, 2024 – 2032 (USD Million) 92
18.3. Diabetes Types 93
18.3.1. UAE DIABETES DRUGS Market Revenue, By Diabetes Types, 2018 – 2023 (USD Million) 93
18.3.2. UAE DIABETES DRUGS Market Revenue, By Diabetes Types, 2024 – 2032 (USD Million) 93
18.4. Route Of Administration 94
18.4.1. UAE DIABETES DRUGS Market Revenue, By Route Of Administration , 2018 – 2023 (USD Million) 94
18.4.2. UAE DIABETES DRUGS Market Revenue, By Route Of Administration , 2024 – 2032 (USD Million) 94
18.5. Technology 95
18.5.1. UAE DIABETES DRUGS Market Revenue, By Technology, 2018 – 2023 (USD Million) 95
18.5.2. UAE DIABETES DRUGS Market Revenue, By Technology, 2024 – 2032 (USD Million) 95
18.6. Distribution Channel 96
18.6.1. UAE DIABETES DRUGS Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 96
18.6.2. UAE DIABETES DRUGS Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 96 CHAPTER NO. 19 : COMPANY PROFILES 97
19.1. Novo Nordisk A/S 97
19.1.1. Company Overview 97
19.1.2. Product Portfolio 97
19.1.3. Swot Analysis 97
19.1.4. Business Strategy 98
19.1.5. Financial Overview 98
19.1.6. Sanofi 99
19.1.7. Merck & Co., Inc 99
19.1.8. Eli Lilly and Company 99
19.1.9. AstraZeneca 99
19.1.10. Takeda Pharmaceutical Company Limited 99
19.1.11. Boehringer Ingelheim International GmbH 99
19.1.12. Novartis AG 99
19.1.13. Johnson & Johnson Services, Inc. 99
19.1.14. Bayer AG 99
19.1.15. NeoBiocon 99
19.1.16. NewBridge Pharmaceuticals FZ LLC 99
19.1.17. Company 13 99
19.1.18. Company 14 99 CHAPTER NO. 20 : RESEARCH METHODOLOGY 100
20.1. Research Methodology 100
20.1.1. Phase I – Secondary Research 101
20.1.2. Phase II – Data Modeling 101 Company Share Analysis Model 102 Revenue Based Modeling 102
20.1.3. Phase III – Primary Research 103
20.1.4. Research Limitations 104 Assumptions 104 List of Figures
FIG NO. 1. UAE DIABETES DRUGS Market Revenue, 2018 – 2032 (USD Million) 22
FIG NO. 2. Porter’s Five Forces Analysis for UAE DIABETES DRUGS Market 29
FIG NO. 3. Value Chain Analysis for UAE DIABETES DRUGS Market 30
FIG NO. 4. UAE DIABETES DRUGS Market Import Volume/Revenue, By UAE, 2018 – 2023 32
FIG NO. 5. UAE DIABETES DRUGS Market Export Volume/Revenue, By UAE, 2018 – 2023 33
FIG NO. 6. UAE DIABETES DRUGS Market Demand Volume/Revenue, By UAE, 2018 – 2023 34
FIG NO. 7. UAE DIABETES DRUGS Market Supply Volume/Revenue, By UAE, 2018 – 2023 35
FIG NO. 8. UAE DIABETES DRUGS Market Production Volume/Revenue, By UAE, 2018 – 2023 36
FIG NO. 9. UAE DIABETES DRUGS Market Price, By Drug Class, 2018 – 2023 37
FIG NO. 10. Raw Materials Price Trend Analysis, 2018 – 2023 38
FIG NO. 11. Manufacturing Cost Analysis 39
FIG NO. 12. Manufacturing Process 39
FIG NO. 13. Company Share Analysis, 2023 40
FIG NO. 14. Company Share Analysis, 2023 41
FIG NO. 15. Company Share Analysis, 2023 41
FIG NO. 16. Company Share Analysis, 2023 42
FIG NO. 17. DIABETES DRUGS Market – Company Volume Market Share, 2023 43
FIG NO. 18. DIABETES DRUGS Market – Company Revenue Market Share, 2023 44
FIG NO. 19. DIABETES DRUGS Market Revenue Share, By Drug Class, 2023 & 2032 50
FIG NO. 20. Market Attractiveness Analysis, By Drug Class 51
FIG NO. 21. Incremental Revenue Growth Opportunity by Drug Class, 2024 – 2032 51
FIG NO. 22. DIABETES DRUGS Market Revenue, By Drug Class, 2018, 2023, 2027 & 2032 52
FIG NO. 23. UAE DIABETES DRUGS Market for Insulin, Revenue (USD Million) 2018 – 2032 53
FIG NO. 24. UAE DIABETES DRUGS Market for Dpp-4 Inhibitors, Revenue (USD Million) 2018 – 2032 54
FIG NO. 25. UAE DIABETES DRUGS Market for GLP-1 Receptor Agonists, Revenue (USD Million) 2018 – 2032 55
FIG NO. 26. UAE DIABETES DRUGS Market for SGLT2 Inhibitors, Revenue (USD Million) 2018 – 2032 56
FIG NO. 27. UAE DIABETES DRUGS Market for Others, Revenue (USD Million) 2018 – 2032 57
FIG NO. 28. DIABETES DRUGS Market Revenue Share, By Diabetes Types, 2023 & 2032 59
FIG NO. 29. Market Attractiveness Analysis, By Diabetes Types 60
FIG NO. 30. Incremental Revenue Growth Opportunity by Diabetes Types, 2024 – 2032 60
FIG NO. 31. DIABETES DRUGS Market Revenue, By Diabetes Types, 2018, 2023, 2027 & 2032 61
FIG NO. 32. UAE DIABETES DRUGS Market for Type 1, Revenue (USD Million) 2018 – 2032 62
FIG NO. 33. UAE DIABETES DRUGS Market for Type 2, Revenue (USD Million) 2018 – 2032 63
FIG NO. 34. UAE DIABETES DRUGS Market for Diabetes Types 3, Revenue (USD Million) 2018 – 2032 64
FIG NO. 35. UAE DIABETES DRUGS Market for Diabetes Types 4, Revenue (USD Million) 2018 – 2032 65
FIG NO. 36. UAE DIABETES DRUGS Market for Diabetes Types 5, Revenue (USD Million) 2018 – 2032 66
FIG NO. 37. DIABETES DRUGS Market Revenue Share, By Route Of Administration , 2023 & 2032 68
FIG NO. 38. Market Attractiveness Analysis, By Route Of Administration 69
FIG NO. 39. Incremental Revenue Growth Opportunity by Route Of Administration , 2024 – 2032 69
FIG NO. 40. DIABETES DRUGS Market Revenue, By Route Of Administration , 2018, 2023, 2027 & 2032 70
FIG NO. 41. UAE DIABETES DRUGS Market for Oral, Revenue (USD Million) 2018 – 2032 71
FIG NO. 42. UAE DIABETES DRUGS Market for Subcutaneous, Revenue (USD Million) 2018 – 2032 72
FIG NO. 43. UAE DIABETES DRUGS Market for Intravenous, Revenue (USD Million) 2018 – 2032 73
FIG NO. 44. UAE DIABETES DRUGS Market for Route Of Administration 4, Revenue (USD Million) 2018 – 2032 74
FIG NO. 45. UAE DIABETES DRUGS Market for Route Of Administration 5, Revenue (USD Million) 2018 – 2032 75
FIG NO. 46. DIABETES DRUGS Market Revenue Share, By Technology, 2023 & 2032 77
FIG NO. 47. Market Attractiveness Analysis, By Technology 78
FIG NO. 48. Incremental Revenue Growth Opportunity by Technology, 2024 – 2032 78
FIG NO. 49. DIABETES DRUGS Market Revenue, By Technology, 2018, 2023, 2027 & 2032 79
FIG NO. 50. UAE DIABETES DRUGS Market for Technology 1, Revenue (USD Million) 2018 – 2032 80
FIG NO. 51. UAE DIABETES DRUGS Market for Technology 2, Revenue (USD Million) 2018 – 2032 81
FIG NO. 52. UAE DIABETES DRUGS Market for Technology 3, Revenue (USD Million) 2018 – 2032 82
FIG NO. 53. DIABETES DRUGS Market Revenue Share, By Distribution Channel, 2023 & 2032 84
FIG NO. 54. Market Attractiveness Analysis, By Distribution Channel 85
FIG NO. 55. Incremental Revenue Growth Opportunity by Distribution Channel, 2024 – 2032 85
FIG NO. 56. DIABETES DRUGS Market Revenue, By Distribution Channel, 2018, 2023, 2027 & 2032 86
FIG NO. 57. UAE DIABETES DRUGS Market for Online Pharmacies, Revenue (USD Million) 2018 – 2032 87
FIG NO. 58. UAE DIABETES DRUGS Market for Hospital Pharmacies, Revenue (USD Million) 2018 – 2032 88
FIG NO. 59. UAE DIABETES DRUGS Market for Retail Pharmacies, Revenue (USD Million) 2018 – 2032 89
FIG NO. 60. UAE DIABETES DRUGS Market for Distribution Channel 4, Revenue (USD Million) 2018 – 2032 90
FIG NO. 61. UAE DIABETES DRUGS Market for Distribution Channel 5, Revenue (USD Million) 2018 – 2032 91
FIG NO. 62. Research Methodology – Detailed View 100
FIG NO. 63. Research Methodology 101
List of Tables
TABLE NO. 1. : UAE DIABETES DRUGS Market: Snapshot 18
TABLE NO. 2. : Drivers for the DIABETES DRUGS Market: Impact Analysis 22
TABLE NO. 3. : Restraints for the DIABETES DRUGS Market: Impact Analysis 24
TABLE NO. 4. : UAE DIABETES DRUGS Market Revenue, By Drug Class, 2018 – 2023 34
TABLE NO. 5. : Key Raw Materials & Suppliers 35
TABLE NO. 6. : UAE DIABETES DRUGS Market Revenue, By Drug Class, 2018 – 2023 (USD Million) 89
TABLE NO. 7. : UAE DIABETES DRUGS Market Revenue, By Drug Class, 2024 – 2032 (USD Million) 89
TABLE NO. 8. : UAE DIABETES DRUGS Market Revenue, By Diabetes Types, 2018 – 2023 (USD Million) 90
TABLE NO. 9. : UAE DIABETES DRUGS Market Revenue, By Diabetes Types, 2024 – 2032 (USD Million) 90
TABLE NO. 10. : UAE DIABETES DRUGS Market Revenue, By Route Of Administration , 2018 – 2023 (USD Million) 91
TABLE NO. 11. : UAE DIABETES DRUGS Market Revenue, By Route Of Administration , 2024 – 2032 (USD Million) 91
TABLE NO. 12. : UAE DIABETES DRUGS Market Revenue, By Technology, 2018 – 2023 (USD Million) 92
TABLE NO. 13. : UAE DIABETES DRUGS Market Revenue, By Technology, 2024 – 2032 (USD Million) 92
TABLE NO. 14. : UAE DIABETES DRUGS Market Revenue, By Distribution Channel, 2018 – 2023 (USD Million) 93
TABLE NO. 15. : UAE DIABETES DRUGS Market Revenue, By Distribution Channel, 2024 – 2032 (USD Million) 93
Frequently Asked Questions:
What is the current size of the UAE Diabetes Drugs Market?
The UAE diabetes drugs market was valued at USD 176.85 million in 2023 and is expected to reach USD 198.02 million by 2032, growing at a CAGR of 0.85%.
What factors are driving the growth of the UAE Diabetes Drugs Market?
The market growth is driven by increasing diabetes prevalence, urbanization, government healthcare initiatives, advancements in drug formulations, and the growing adoption of digital health solutions for diabetes management.
What are the key segments within the UAE Diabetes Drugs Market?
The market is segmented by drug class (insulin, DPP-4 inhibitors, GLP-1 receptor agonists, SGLT2 inhibitors, and others), diabetes type (Type 1, Type 2, Type 3, Type 4, and Type 5), route of administration, technology, and distribution channels.
What are some challenges faced by the UAE Diabetes Drugs Market?
Key challenges include high treatment costs, limited public awareness about diabetes management, regulatory hurdles, and accessibility issues in certain regions, which impact the affordability and adoption of advanced diabetes treatments.
Who are the major players in the UAE Diabetes Drugs Market?
Leading pharmaceutical companies include Novo Nordisk, Eli Lilly, Merck & Co., Sanofi, AstraZeneca, Boehringer Ingelheim, Novartis, Johnson & Johnson, Bayer AG, NeoBiocon, and NewBridge Pharmaceuticals.
The report comes as a view-only PDF document, optimized for individual clients. This version is recommended for personal digital use and does not allow printing.
$2699
To meet the needs of modern corporate teams, our report comes in two formats: a printable PDF and a data-rich Excel sheet. This package is optimized for internal analysis and multi-location access, making it an excellent choice for organizations with distributed workforce.
$3699
The report will be delivered in printable PDF format along with the report’s data Excel sheet. This license offers 100 Free Analyst hours where the client can utilize Credence Research Inc.’s research team. It is highly recommended for organizations seeking to execute short, customized research projects related to the scope of the purchased report.
I am very impressed with the information in this report. The author clearly did their research when they came up with this product and it has already given me a lot of ideas.
